Verapamil - Calosyn Pharma

Drug Profile

Verapamil - Calosyn Pharma

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Calosyn Pharma
  • Class Antihypertensives; Antimigraines; Class IV antiarrhythmics; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Musculoskeletal pain

Most Recent Events

  • 18 Apr 2016 No recent reports on development identified - Phase-I/II for Musculoskeletal pain in USA (Intra-articular)
  • 06 Feb 2014 Calosyn Pharma terminates phase I/II trial in Musculoskeletal pain in USA (NCT01645709)
  • 21 Mar 2013 Chemical structure added (USAN); str saved as MOL and PNG files
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top